Sionna Therapeutics (NASDAQ:SION) Director Bruce Booth Sells 169,260 Shares

Key Points

• Bruce Booth, Director of Sionna Therapeutics, sold a total of 169,260 shares for approximately $5.48 million, resulting in an 18.98% decrease in his position in the company.
• Recent trades by Booth include additional shares sold over multiple days, contributing to a substantial amount of liquidity exchanged within the stock during the past month.
• Sionna Therapeutics' stock has shown a 12-month price range between $7.26 and $34.00, with current trading around $32.20.

Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) Director Bruce Booth sold 169,260 shares of the firm's stock in a transaction on Thursday, October 16th. The shares were sold at an average price of $32.35, for a total transaction of $5,475,561.00. Following the transaction, the director owned 722,301 shares in the company, valued at $23,366,437.35. This represents a 18.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Bruce Booth also recently made the following trade(s):

• On Monday, October 20th, Bruce Booth sold 55,985 shares of Sionna Therapeutics stock. The shares were sold at an average price of $32.09, for a total transaction of $1,796,558.65.
• On Friday, October 17th, Bruce Booth sold 61,124 shares of Sionna Therapeutics stock. The shares were sold at an average price of $32.37, for a total transaction of $1,978,583.88.
• On Wednesday, October 15th, Bruce Booth sold 115,856 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.61, for a total transaction of $3,546,352.16.
• On Tuesday, October 14th, Bruce Booth sold 606 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total transaction of $18,149.70.
• On Monday, October 13th, Bruce Booth sold 58,232 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.38, for a total transaction of $1,769,088.16.
• On Friday, October 10th, Bruce Booth sold 20,238 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.98, for a total transaction of $606,735.24.
• On Monday, October 6th, Bruce Booth sold 11,800 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total transaction of $353,410.00.
• On Friday, October 3rd, Bruce Booth sold 37,746 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.00, for a total transaction of $1,132,380.00.
• On Wednesday, October 1st, Bruce Booth sold 200 shares of Sionna Therapeutics stock. The shares were sold at an average price of $29.95, for a total transaction of $5,990.00.
• On Tuesday, September 30th, Bruce Booth sold 12,388 shares of Sionna Therapeutics stock. The shares were sold at an average price of $30.06, for a total transaction of $372,383.28.

Sionna Therapeutics Stock Performance

SION traded up $0.27 during trading on Monday, hitting $32.20. The stock had a trading volume of 222,456 shares, compared to its average volume of 325,019. Sionna Therapeutics, Inc. has a 12 month low of $7.26 and a 12 month high of $34.00. The company has a 50 day simple moving average of $25.76 and a 200-day simple moving average of $18.76.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.27.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. bought a new position in shares of Sionna Therapeutics during the 1st quarter worth about $109,258,000. TPG GP A LLC acquired a new stake in shares of Sionna Therapeutics during the 1st quarter valued at about $69,925,000. Atlas Venture Life Science Advisors LLC acquired a new stake in shares of Sionna Therapeutics during the 1st quarter valued at about $38,639,000. Viking Global Investors LP boosted its position in shares of Sionna Therapeutics by 8.2% during the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company's stock valued at $55,436,000 after acquiring an additional 242,427 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Sionna Therapeutics by 2.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,221,188 shares of the company's stock valued at $38,538,000 after acquiring an additional 51,589 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Wall Street Zen upgraded shares of Sionna Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. Royal Bank Of Canada assumed coverage on shares of Sionna Therapeutics in a report on Wednesday, September 3rd. They issued a "sector perform" rating and a $22.00 target price on the stock. Jones Trading assumed coverage on shares of Sionna Therapeutics in a report on Monday, September 8th. They issued a "buy" rating and a $46.00 target price on the stock. Weiss Ratings reiterated a "sell (d)" rating on shares of Sionna Therapeutics in a report on Wednesday, October 8th. Finally, Raymond James Financial began coverage on shares of Sionna Therapeutics in a report on Tuesday, September 2nd. They set a "strong-buy" rating and a $45.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Sionna Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $38.00.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.